Intestinal gel for Parkinson's mood and behavior problems
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a gel form of levodopa (called Lecigon) given through a tube into the intestine to see if it helps reduce mood swings, impulsive behaviors, and other mental side effects in people with Parkinson's who already have motor fluctuations. It is for people who have had Parkinson's for at least 5 years and are between 18 and 75 years old.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Parkinson's disease for at least 5 years, and your symptoms started before age 65.
- You are between 18 and 75 years old.
- You take a steady dose of levodopa and a dopamine agonist (a type of Parkinson's medication) for at least 4 weeks.
- You experience motor fluctuations (wearing off or unpredictable on-off periods) and mood or behavioral changes related to your Parkinson's medication.
- You have a score of 3 or higher on a specific behavioral scale, meaning you have noticeable impulsive or psychotic-like symptoms (but you still have insight into them).
- You agree to use highly effective contraception if needed, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new single-dose treatment for Parkinson's disease to see if it can help reduce 'off' time—when medication wears off and symptoms return. It is for people who experience motor fluctuations and are already on a stable medication routine.
This trial tests a new gene therapy delivered directly into the brain to help control Parkinson's symptoms. It is for people with advanced Parkinson's disease who still have significant movement problems despite their current medications.
This study looks at the gut and intestinal lining in people with Parkinson's who have not yet started treatment, compared with healthy people. It may help us understand how the gut relates to Parkinson's and could lead to better treatments.
This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.
This study looks at how the bacteria in your gut (microbiome) might affect how well levodopa works for Parkinson's disease. You will swallow a small capsule that collects samples as it travels through your intestine, which helps researchers understand your gut health.
This trial tests a new oral medication, VG081821AC, in people with early to mid-stage Parkinson's disease. The goal is to see if it can improve movement symptoms and slow the progression of the condition, and it may offer a new treatment option for those not yet on levodopa.
Hear when a new PARKINSON DISEASE (Disorder) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.